Neoplasm: Clinical Trials

7 trials for Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated. 7 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Terminated 7
Phase 16Terminated 6

Follow Neoplasm: new trials by email Literature Review of Neoplasm trials Research Report on Neoplasm

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
SAR444200, Atezolizumab - Neoplasm
Phase 1 / Phase 2TerminatedSanofi332022-09-202026-01-14
The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
5-Aminolevulinic acid Hydrochloride - Neoplasm, Skull Base Neoplasm
Phase 2TerminatedIcahn School of Medicine at Mount Sinai72021-09-142025-07-28
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
SAR444881, Pembrolizumab, Cetuximab - Cancer, Neoplasm
Phase 1 / Phase 2TerminatedSanofi1252021-04-112026-09-29
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
Isatuximab SAR650984, Atezolizumab - Neoplasm
Phase 1 / Phase 2TerminatedSanofi1072018-08-062023-07-10
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors
Phase 1 / Phase 2TerminatedBristol-Myers Squibb802017-09-012023-02-28
Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy
Topical Phenylephrine Solution - Neoplasm, Oral Mucosa
Phase 1 / Phase 2TerminatedUniversity of Wisconsin, Madison32015-05-142019-12-09
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
Phase 1 / Phase 2TerminatedAsana BioSciences512015-05-012023-06-07

Narrower conditions

Neoplasms (7)  ·  Head and Neck Neoplasms (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell, Peripheral (1)  ·  Primary Myelofibrosis (1)  ·  Skull Base Neoplasms (1)

Broader conditions

Bone Diseases (1)  ·  Bone Marrow Diseases (1)  ·  Bone Neoplasms (1)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia (1)  ·  Leukemia, B-Cell (1)  ·  Leukemia, Lymphoid (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphoproliferative Disorders (1)

Interventions

atezolizumab (2)  ·  Aminolevulinic Acid (1)  ·  Carboplatin (1)  ·  Cetuximab (1)  ·  Ipilimumab (1)  ·  Nivolumab (1)  ·  Pemetrexed (1)  ·  Tetanus Toxoid (1)  ·  isatuximab (1)  ·  pembrolizumab (1)

Sponsors

Sanofi (3)  ·  Asana BioSciences (1)  ·  Bristol-Myers Squibb (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (7)  ·  Canada (4)  ·  Spain (2)  ·  Argentina (1)  ·  Belgium (1)  ·  China (1)  ·  Czechia (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Switzerland (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Alfred-Marc Iloreta, MD (1)  ·  Margo L. Hoover-Regan (1)  ·  Niranjan Rao, PhD (1)

Results publications

PMID 36096532

NIH funding

2017 (1), 2018 (1), 2023 (1)